Cervical cancer is the most common gynecologic malignancy worldwide. Squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma are the three major histologic types, and this cancer develops slowly and locally. Radical hysterectomy plus pelvic lymph node dissection or concurrent chemoradiation therapy (CCRT) is the standard treatment when the disease is at an early stage. CCRT remains the standard for locally advanced disease, and systemic chemotherapy plays a major role in disease with distant metastases. In recent decades, some new trends in treating this cancer have been discussed and applied. A series of clinical trials and retrospective studies support a more conservative surgical treatment in early-stage disease. Sentinel lymph node mapping is used to decrease the morbidities after nodal dissection. Some new concurrent chemotherapeutic agents and schedules have been developed to replace the traditional cisplatin-base agents in order to decrease the toxicity during CCRT. Consolidation chemotherapy after CCRT can help improve the outcome. Neoadjuvant chemotherapy plus radiotherapy has revealed itself as the potential application as part of a new therapeutic trend in treating locally advanced cervical cancer patients. In the Gynecologic Oncology Group (GOG) phase III trial (GOG-179), cisplatin plus topotecan was proved to prolong the patients' survival time. Vaccines, both prophylactic and therapeutic, will be the trend in the future. This article intends to review recent reports and update the available information relating to the current trends in the management of cervical cancer.
Introduction
Cervical cancer is the most common gynecologic malignancy in Taiwan. The incidence of cervical cancer is 51.88/100,000 women in 2002 1 . Over 99% of cervical cancers are caused by the high-risk group of human papillomavirus (HPV) 2 , which includes types 16 and 18 that are responsible for over 70% of cervical cancer. Quadrivalent (Gardasil®; Merck & Co., NJ, USA) and bivalent (Cervarix®; GlaxoSmithKline, London, UK) HPV vaccines are recently available treatments for prevention of cervical infection of the two high-risk HPV types before the onset of pre-cancer lesion (cervical intraepithelial neoplasm [CIN] ). Cervical cancer is also a slowly progressing local disease, which occurs 5-30 years after the development of CIN lesions. CIN lesions can be detected by Papanicolaou smear and treated with local excision procedure or simple hysterectomy. Unfortunately, if CIN lesions develop into invasive cancer, the treating modalities become more complicated, and usually at a sacrifice to the quality of life of these cervical cancer patients. We would like to review the modern trends in the treatment of invasive cervical cancer.
within the cervical portion to the upper vagina without parametrial involvement. There are 3 main histologic types of cervical cancer: squamous cell carcinoma (SCC), adenocarcinoma, and adenosquamous cell carcinoma. SCC offers a better prognosis and allows for more conservative modalities than the other two types. Stage IA1 SCC cervical cancer can be treated by conization with the intention of preserving the uterus if fertility is desired, because the possibility of pelvic lymph node metastases is < 1% 3 . Simple hysterectomy without pelvic lymph node dissection is acceptable if fertility is no longer a concern. On the other hand, the management of adenocarcinoma and adenosquamous cell carcinoma remains as conization followed by hysterectomy, for fear of a skip lesion in the cervical portion.
The traditional treatment of stage IA2 cervical cancer is class 2 radical hysterectomy (modified radical hysterectomy) with pelvic lymph node dissection. Alternatively, unlike adenocarcinoma or adenosquamous carcinoma, radical trachelectomy with pelvic node dissection is acceptable for SCC cervical cancer if fertility preservation is desired, because the probability of a nodal metastasis averages 7.3% 4 . The conventional treatment of stage IB1 or IIA tumors (4 cm or less in diameter) requires class III Wertheim's radical hysterectomy plus bilateral pelvic lymph node dissection. Yang et al. 5 suggested a more conservative modality, which employed class II radical hysterectomy (modified radical hysterectomy) and yielded results comparable to the traditional surgical method with low voiding or defecation dysfunction. The local failure rate was not increased and the complication rate was decreased if postoperative radiotherapy was required. The local recurrence in one adenocarcinoma patient revealed that conservative modalities were unsuitable for histologic types other than SCC. Patients with stage IB2 or IIA tumors (4 cm or more in diameter) were favorably treated with concurrent chemoradiation therapy (CCRT) than those receiving large-scale surgeries 6, 7 . There was a 30-40% possibility of pelvic lymph node metastases, and postoperative radiotherapy was eventually unavoidable. The morbidity of surgery plus CCRT was higher than surgery or CCRT alone. The quality of life became worse in the combination group. It has been suggested that pelvic lymph node dissection will not increase the complication during consecutive CCRT and that the excision of existing bulky nodes is beneficial.
Trend 2: CCRT
Ever since 1988, CCRT has replaced the traditional radiotherapy and become the standard primary treatment of locally advanced cervical cancer (stages IIB-IVA). When a combination of cisplatin and 5-fluorouracil (5-FU) was used as radiosensitizers during pelvic radiation and brachytherapy, the local control rate, progressive-free survival, and overall survival were improved. Although the cisplatin-5-FU combination incurred other treatment morbidities such as severe bone marrow suppression, this morbidity had been shown to be acceptable in a recent literature 8 .
CCRT was also shown to be applicable in earlystage cervical cancer patients who were not suitable for radical surgery or had major risk factors after radical surgery. The schedule of chemotherapy during radiotherapy is cisplatin plus 5-FU for three courses with a 21-day interval between the courses, or a singleagent cisplatin (40 mg/m 2 ) given weekly for six courses. Ikushima et al. 9 reported that the reduction of the weekly cisplatin dose to 30 mg/m 2 significantly reduced hematologic toxicity. A new chemotherapeutic schedule of daily cisplatin (20 mg/m 2 /d for 5 consecutive days) for a total of two courses during radiotherapy has been developed, and it was reported to have a better outcome 10 . Other chemotherapeutic agents, such as gemcitabine, oxaliplatin, etoposide, liposomal doxorubicin, carboplatin and tagafur, or paclitaxel, and carboplatin, were tested as radiosensitizers, but cisplatin remains the most effective agent in treating cervical cancer 11 .
Trend 3: Sentinel Lymph Node-Mapping
Sentinel lymph node mapping is well developed for the surgery of breast cancer, for the reduction of morbidity after total axillary lymph node dissection. Similarly, this procedure is currently applied during radical surgery of cervical cancer to reduce the lower-extremity lymphedema, lymphagitis or pelvic lymphocyst after pelvic lymph node dissection and is often coupled with postoperative pelvic radiotherapy. Metastable technetium-99 (Tc-99m) lymphoscintigraphy and blue dye injection are used to investigate the sentinel lymph node distribution during pelvic node dissection. A recent study by Wydra et al. 12 reported the sensitivity (86.4%), negative predictive value (95.5%), and specificity (100%) using a ) and cisplatin (75 mg/m 2 ) was used concurrently during two low-dose rate brachytherapy applications. After completing concomitant chemoradiation therapy, four courses of systemic chemotherapy with the same two-drug regimen were given as consolidation therapy. The results showed a high response rate (nearly 100%) and high recurrence-free rate (88.7%) during a follow-up of 49 months. The trial also demonstrated acceptable morbidity rate (25% grade 3, 11% grade 4 hematologic toxicities). Only 16% of the patients developed delayed major complications. This protocol may become more promising than the traditional CCRT schedule.
Trend 5: Neoadjuvant Chemotherapy (NACT)
NACT plus surgery have demonstrated itself on phase II trials to be feasible as a valid replacement for conventional radiotherapy or surgery [14] [15] [16] . However, most phase III trials of NACT plus radiotherapy have failed to show further benefit than those of radiotherapy alone 17 . In contrast, a recent meta-analysis by Medical Research Council (UK) 18 showed the benefit of a more intensive chemotherapy at shorter cycle length or higher dose intensity for the NACT plus radiotherapy treatment.
This meta-analysis included 2,074 patients from 18 different trials with a median follow-up analysis of 5.7 years. Sardi et al. 19 , in a recent review article, drew attention to the significance of this meta-analysis and highlighted the potential application of NACT plus radiotherapy as part of a new therapeutic trend in treating locally advanced cervical cancer patients. Further research is required to verify and conclude this finding.
Trend 6: Improvement of Systemic Chemotherapy
Single-agent cisplatin (50 mg/m 2 ) administered every 3 weeks apart has been the standard systemic chemotherapeutic agent for the treatment of advanced/recurrent and metastatic SCC of the uterine cervix. It demonstrated a 50% objective response rate in previously untreated patients 20 . Several new single agents with antineoplastic activity were trialed in combination with cisplatin, including ifosfamide 21 , oxaliplatin, paclitaxel 22 , and gemcitabine 23 . Ifosfamide plus cisplatin demonstrated a significant improvement in response rate and progressive-free survival but failed to improve the overall survival 24 . The combination of ifosfamide and cisplatin showed limited improvement on the progressive-free survival (1.4 months). A recent Gynecologic Oncology Group (GOG)-169 study 25 demonstrated that a combination of paclitaxel and cisplatin also showed limited improvement in progressive-free survival without any improvement in overall survival. The abovementioned trials once again reinforce the role of single-agent cisplatin as the current standard systemic therapy for cervical cancer. There have been two new trends in multiple chemotherapeutic agent combinations recently, the first is the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) 26 , and the other is cisplatin plus topotecan (GOG-179) 27 . The three-arm clinical trial involving the MVAC regimen was forced to close prematurely because of many treatment-related deaths. In the comparison between cisplatin plus topotecan and single-agent cisplatin, the combination group showed a statistically significant improvement in response rate (27% vs. 13%), progressive-free survival (4.6 months vs. 2.9 months) and overall survival (9.4 months vs. 6.5 months). The combination of cisplatin plus topotecan has now replaced the single-agent cisplatin to become the most effective systemic chemotherapeutic combination agents. . These therapeutic vaccines can be divided to several subgroups 29 , such as viral-vector, bacterial-vector, peptide, protein, DNA, dendrite cell-based, and tumor cell-based. A number of approaches have shown significant therapeutic benefit in preclinical papillomavirus models 16 . Although the therapeutic vaccines might have efficiency similar to surgical treatment of CIN 30 , the current therapeutic vaccine trials are still less mature with respect to disease clearance. Further testing in patient populations is required to determine the most effective curative strategy.
Trend 8: Molecular/target Drugs
Advances in molecular biology have led to the discovery of a number of cancer pathways. Having gained substantial understanding of the mechanisms of cell proliferation, cell cycle regulation, apoptosis, angiogenesis and inflammation, pharmaceutical companies have developed several kinds of molecular or protein drugs to target the key enzymes, growth factors or receptors in order to block these pathways. For example, erlotinib (OSI-774) is an endothelial growth factor receptor tyrosine kinase inhibitor, which has been used to treat cervical cancer 31 . Although only limited drugs are clinically useful in the treatment of breast cancer, lung cancer or other solid tumors, many newly developed drugs are now undergoing further experiments. Target therapy can play either a major or an assistant role in the future treatments of cancers, including cervical cancer and other gynecologic malignancies.
Conclusion
This review summarizes the current trends in the management of cervical cancer. Although the results of some clinical trials are still inconclusive, many clinical improvements have been observed in recent years. It is the author's belief that the investigation of alternate treatment modalities that are more conservative, less toxic, less harmful, and more effective is an ongoing objective in the field of gynecologic oncology.
